mocetinostat + brentuximab vedotin

Mocetinostat + brentuximab vedotin is an investigational combination therapy for cancer, particularly in relapsed or refractory Hodgkin lymphoma. Mocetinostat is a small molecule histone deacetylase (HDAC) inhibitor that modulates gene expression and induces apoptosis in cancer cells. Brentuximab vedotin is an antibody-drug conjugate consisting of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Brentuximab vedotin binds to CD30-expressing tumor cells, is internalized, and releases MMAE intracellularly to disrupt microtubules, causing cell cycle arrest and apoptosis[2][3][6]. The combination aims to enhance antitumor activity by targeting both epigenetic regulation (via HDAC inhibition) and direct cytotoxicity against CD30-positive lymphoma cells.